Nonalcoholic steatohepatitis is a common disease involving chronic accumulation of fat and inflammation in the liver, often leading to advanced fibrosis, cirrhosis, and cancer. It is known that nonalcoholic steatohepatitis shares many features with atherosclerosis; however, there are still no effective therapeutics. In a recent study published in Nature, investigators demonstrated that mice lacking a high-density lipoprotein-associated gene were surprisingly protected from both steatohepatitis and atherosclerosis through the stabilization of the liver X receptor. This work reveals a timely candidate target for 2 highly prevalent cardiovascular diseases. (J Am Coll Cardiol Basic Trans Science 2016;1:680-3)
now identified over 150 independent loci, many of which have been subjected to fine-mapping meta-analyses in nearly 200,000 individuals. The rate-limiting step remains in the functional interpretation of these loci, ultimately to identify the underlying causal variants, genes, and disease-relevant mechanisms responsible for driving the complex trait(s) (3).
For instance, a genetic variant in the intron of a gene encoding tetratricopeptide repeat domain protein 39B (TTC39B or T39) was previously associated with HDL cholesterol in 1 of these large metaanalyses; however, there were no obvious hints as to its connection to HDL regulation other than a Manuscript received September 28, 2016; accepted September 28, 2016. inhibition is an attractive therapeutic approach to promote a favorable hepatic lipid profile and block atherosclerosis.
